14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
DARE vs GNPX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Genprex, Inc. (GNPX) captures the overall head-to-head institutional edge over Dare Bioscience, Inc. (DARE) on higher Unified Composite conviction (42.2/100 HOLD vs. 45.4/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality), while DARE wins 3–1 across the 6-pillar growth and valuation breakdown. DARE trades at $0.41 (1.3x Forward P/E, -746.1% operating margin) versus GNPX at $1.45 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While DARE currently prints a higher short-term Unified Composite Score (45.4/100 HOLD vs. GNPX 42.2/100 HOLD), GNPX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -746.1% operating margin) and revenue trajectory (+0.0% vs. +2005.6% YoY).
Technical & Structure Timing Caution: DARE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.4); meanwhile GNPX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DARE vs GNPX. Trailing 12-month operating profitability (DARE -746.1% vs GNPX 0.0%) and valuation multiples (DARE 1.3x vs GNPX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ DARE vs GNPX Key Questions & Quantitative Answers
As of Nov 20, 2026, Genprex, Inc. (GNPX) captures the overall head-to-head institutional edge over Dare Bioscience, Inc. (DARE) on higher Unified Composite conviction (42.2/100 HOLD vs. 45.4/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality), while DARE wins 3–1 across the 6-pillar growth and valuation breakdown. DARE trades at $0.41 (1.3x Forward P/E, -746.1% operating margin) versus GNPX at $1.45 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While DARE currently prints a higher short-term Unified Composite Score (45.4/100 HOLD vs. GNPX 42.2/100 HOLD), GNPX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -746.1% operating margin) and revenue trajectory (+0.0% vs. +2005.6% YoY). Technical & Structure Timing Caution: DARE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.4); meanwhile GNPX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DARE leads the Growth & Scale pillar: DARE posts +2005.6% YoY revenue growth and +0.0% YoY earnings growth on $1.4M TTM revenue (N/A gross margin, -746.1% operating margin), compared with GNPX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, DARE generates $1.4M in USD-normalized revenue versus N/A for GNPX. In operating R&D and SG&A reinvestment, DARE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GNPX.
DARE screens cheaper on headline valuation multiples. DARE trades at 1.3x Forward P/E, 1.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas GNPX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DARE (-407.1% ROE) versus GNPX (-233.7% ROE) capital efficiency.
In options market volatility and institutional positioning, DARE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.59β · 112% Vol realized risk). By comparison, GNPX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-4.68β · 96% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.